Treatment for neovascular age related macular degeneration: The state of the art.

Details

Serval ID
serval:BIB_B12577C45235
Type
Article: article from journal or magazin.
Collection
Publications
Title
Treatment for neovascular age related macular degeneration: The state of the art.
Journal
European journal of pharmacology
Author(s)
Eandi C.M., Alovisi C., De Sanctis U., Grignolo F.M.
ISSN
1879-0712 (Electronic)
ISSN-L
0014-2999
Publication state
Published
Issued date
15/09/2016
Peer-reviewed
Oui
Volume
787
Pages
78-83
Language
english
Notes
Publication types: Journal Article ; Review
Publication Status: ppublish
Abstract
With the introduction in the clinical practice of drugs inhibiting vascular endothelial growth factor (VEGF) the visual outcomes of patients with neovascular age related macular degeneration (AMD) dramatically improved. Since 2006 repeated intravitreal injections of anti-VEGF became the standard of care for the treatment of neovascular AMD. This review provides an overview of available data form clinical trials supporting the use of anti-VEGF molecules for the treatment of this condition. Several questions remain open, in particular the regimen of treatment, the frequency of injection, the safety of the different drugs, and the poor response to the treatment in some cases. Therefore, new agents and alternative delivery are currently under evaluation.
Keywords
Animals, Blood Vessels/drug effects, Blood Vessels/metabolism, Blood Vessels/physiopathology, Clinical Trials as Topic, Humans, Macular Degeneration/drug therapy, Macular Degeneration/metabolism, Macular Degeneration/physiopathology, Molecular Targeted Therapy/adverse effects, Molecular Targeted Therapy/methods, Safety, Vascular Endothelial Growth Factor A/metabolism, Angiogenesis, Anti-VEGF, Choroid, Degeneration, Macula, Retina
Pubmed
Web of science
Create date
12/03/2021 19:13
Last modification date
26/03/2021 7:35
Usage data